Making a therapeutic choice: Human versus recombinant fractions - Can we do it?

Haemophilia

Volumn 7, Issue SUPPL. 1, 2001, Pages 1-3

  Aledort, L M ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Factor XI deficiency; Haemophilia; Immune tolerance induction; Plasma derived clotting factors; Recombinant factor concentrates; Recombinant factor VIIa

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CONTAMINATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CHOICE; DRUG COST; DRUG MANUFACTURE; DRUG SAFETY; FRACTIONATION; HUMAN; IMMUNOLOGICAL TOLERANCE; MEDICAL DECISION MAKING; PLASMA; PRIORITY JOURNAL; TECHNIQUE; THROMBOSIS; VIRUS INACTIVATION; VON WILLEBRAND DISEASE;

EID: 0035122987     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00095.x     Document Type: Article

References (10)

1. BPL factor XI concentrate: Clinical experience in the USA
2. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
3. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A
4. Inhibitors in hemophilia patients: Current status and management
5. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations
6. R vs. Benefix™) in previously treated subjects with moderate or severe hemophilia B
7. Albumin-free formulated recombinant factor VIII preparations-how big a step forward?
8. Immune tolerance in hemophilia-principal results from the international registry: Report of the Factor VIII and IX Subcommittee
9. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
10. rVIIa - Its thrombogenicity